Ciclosporin in psoriasis clinical practice: an international consensus statement
dc.contributor.author | Griffiths, Christopher E. M. | en_US |
dc.contributor.author | Dubertret, L. | en_US |
dc.contributor.author | Ellis, C. N. | en_US |
dc.contributor.author | Finlay, A. Y. | en_US |
dc.contributor.author | Finzi, A. F. | en_US |
dc.contributor.author | Ho, Vincent C. | en_US |
dc.contributor.author | Johnston, A. | en_US |
dc.contributor.author | Katsambas, A. | en_US |
dc.contributor.author | Lison, A-E. | en_US |
dc.contributor.author | Naeyaert, J. M. | en_US |
dc.contributor.author | Nakagawa, H. | en_US |
dc.contributor.author | Paul, C. | en_US |
dc.contributor.author | Vanaclocha, F. | en_US |
dc.date.accessioned | 2010-06-01T18:21:25Z | |
dc.date.available | 2010-06-01T18:21:25Z | |
dc.date.issued | 2004-05 | en_US |
dc.identifier.citation | Griffiths, C.E.M.; Dubertret, L.; Ellis, C.N.; Finlay, A.Y.; Finzi, A.F.; Ho, V.C.; Johnston, A.; Katsambas, A.; Lison, A-E.; Naeyaert, J.M.; Nakagawa, H.; Paul, C.; Vanaclocha, F. (2004). "Ciclosporin in psoriasis clinical practice: an international consensus statement." British Journal of Dermatology 150(s67): 11-23. <http://hdl.handle.net/2027.42/71566> | en_US |
dc.identifier.issn | 0007-0963 | en_US |
dc.identifier.issn | 1365-2133 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/71566 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15115441&dopt=citation | en_US |
dc.description.abstract | The main recommendations for the use of ciclosporin in the management of psoriasis are: (i) intermittent short courses (average of 12 weeks duration) of ciclosporin are preferable; (ii) ciclosporin should be given in the dose range 2·5–5·0 mg kg −1 day −1 (doses greater than 5·0 mg kg −1 day −1 should only be given in exceptional circumstances); (iii) treatment regimens should be tailored to the needs of each patient; (iv) selection of patients should take into account psychosocial disability, as well as clinical extent of disease and failure of previous treatment; (v) each patient's renal function (as measured by serum creatinine) should be thoroughly assessed before and during treatment; (vi) each patient's blood pressure should be carefully monitored before and during treatment; (vii) adherence to treatment guidelines substantially reduces the risk of adverse events; (viii) long-term continuous ciclosporin therapy may be appropriate in a subgroup of patients; however, duration of treatment should be kept below 2 years whenever possible; and (ix) when long-term continuous ciclosporin therapy is necessary, annual evaluation of glomerular filtration rate may be useful to accurately monitor renal function. | en_US |
dc.format.extent | 217345 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2004 British Association of Dermatologists | en_US |
dc.subject.other | Calcineurin Inhibitor | en_US |
dc.subject.other | Ciclosporin | en_US |
dc.subject.other | Clinical Practice | en_US |
dc.subject.other | Consensus | en_US |
dc.subject.other | Psoriasis | en_US |
dc.title | Ciclosporin in psoriasis clinical practice: an international consensus statement | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | † Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | * Skin Research Institute and Dermatology, Saint Louis University Hospital, Paris, France | en_US |
dc.contributor.affiliationother | † Department of Dermatology, University of Wales College of Medicine, Cardiff, UK | en_US |
dc.contributor.affiliationother | § Department of Dermatology, University of Milan, Milan, Italy | en_US |
dc.contributor.affiliationother | ¶ Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada | en_US |
dc.contributor.affiliationother | ** Clinical Pharmacology, Barts and The London, University of London, UK | en_US |
dc.contributor.affiliationother | †† Department of Dermatology, University of Athens, A.Sygros Hospital, Athens, Greece | en_US |
dc.contributor.affiliationother | †† Department of Nephrology and Transplantation, Medizinische Klinik III, Zentralkrankenhaus, Bremen, Germany | en_US |
dc.contributor.affiliationother | §§ Department of Dermatology, Ghent University Hospital, Gent, Belgium | en_US |
dc.contributor.affiliationother | ¶¶ Department of Dermatology, Jichi Medical School, Tochigi, Japan | en_US |
dc.contributor.affiliationother | *** Clinical Research Department, Novartis Pharma AG, Basel, Switzerland, and Department of Dermatology, Mulhouse General Hospital, Mulhouse, France | en_US |
dc.contributor.affiliationother | ††† Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain | en_US |
dc.identifier.pmid | 15115441 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/71566/1/j.0366-077X.2004.05949.x.pdf | |
dc.identifier.doi | 10.1111/j.0366-077X.2004.05949.x | en_US |
dc.identifier.source | British Journal of Dermatology | en_US |
dc.identifier.citedreference | Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 40. | en_US |
dc.identifier.citedreference | Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 1996; 135: 775 – 7. | en_US |
dc.identifier.citedreference | Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CEM. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000; 142: 728 – 32. | en_US |
dc.identifier.citedreference | Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the Psoriasis Quality of Life Questionnaire. Dermatol Psychosom 2002; 3: 171 – 9. | en_US |
dc.identifier.citedreference | Zachariae R, Zachariae H, Blomqvist K et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002 June; 146: 1006 – 16. | en_US |
dc.identifier.citedreference | Hermansen SE, Helland CA, Finlay AY. Patients' and doctors' assessment of skin disease handicap. Clin Exp Dermatol 2002; 27: 249 – 50. | en_US |
dc.identifier.citedreference | Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736 – 42. | en_US |
dc.identifier.citedreference | Renzi C, Picardi A, Abeni D et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337 – 42. | en_US |
dc.identifier.citedreference | Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581 – 3. | en_US |
dc.identifier.citedreference | Fortune DG, Richards HL, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003; 139: 752 – 6. | en_US |
dc.identifier.citedreference | Krueger GG, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281 – 5. | en_US |
dc.identifier.citedreference | Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CEM. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72 – 6. | en_US |
dc.identifier.citedreference | Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280 – 4. | en_US |
dc.identifier.citedreference | Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis: results of a multi-dose, double-blind trial. N Engl J Med 1991; 324: 277 – 84. | en_US |
dc.identifier.citedreference | Finzi AF, ed. Cyclosporin in severe psoriasis: The Italian experience. Dermatology, 1993: 187 ( Suppl. 1 ). | en_US |
dc.identifier.citedreference | Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short-course cyclosporin (Neoral ® ). A multicentre study. Br J Dermatol 1997; 136: 527 – 30. | en_US |
dc.identifier.citedreference | Ho VCY, Albrecht G, Vanaclocha F et al. Intermittent short courses of cyclosporin (Neoral ® ) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol 1999; 141: 283 – 91. | en_US |
dc.identifier.citedreference | Ho VCY, Griffiths CEM, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643 – 51. | en_US |
dc.identifier.citedreference | Faerber L, Braeutigam M, Weidinger G et al. Cyclosporine in severe psoriasis: Results of a meta-analysis. Am J Clin Dermatol 2001; 2: 41 – 7. | en_US |
dc.identifier.citedreference | Touw CR, Hakkaart-Van Roijen L, Paul C, Rutten EFH, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967 – 72. | en_US |
dc.identifier.citedreference | Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997; 36: 423 – 32. | en_US |
dc.identifier.citedreference | Koo J, OLP302 Study Group. A randomised, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol 1998; 139: 88 – 95. | en_US |
dc.identifier.citedreference | Powles AV, Baker BS, Valdimarsson H, Hulme B, Fry L. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol 1990; 36 ( Suppl. ): 13 – 9. | en_US |
dc.identifier.citedreference | Ohtsuki M, Nakagawa H, Sugai J et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol 2003; 30: 290 – 8. | en_US |
dc.identifier.citedreference | Mrowietz U, Faerber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol 1995; 33: 470 – 5. | en_US |
dc.identifier.citedreference | Vanaclocha F, Puig L, DaudÉn E et al. Effectiveness of cyclosporine in patients with psoriasis. 9th International Psoriasis Symposium, New York, June 17–22, 2003. | en_US |
dc.identifier.citedreference | Puig L, Vanaclocha F, DaudÉn E et al. Quality of life in psoriatic patients treated with cyclosporine. 9th International Psoriasis Symposium, New York, June 17–22, 2003. | en_US |
dc.identifier.citedreference | Mihatsch MJ, Belghiti D, Bohman SO et al. Kidney biopsies in control or cyclosporin A treated psoriatic patients. Br J Dermatol 1990; 122: 95 – 100. | en_US |
dc.identifier.citedreference | Lowe NJ, Wieder JM, Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1997; 37: 671 – 2. | en_US |
dc.identifier.citedreference | Mihatsch MJ, Wolff K. A consensus report: cyclosporin A therapy for psoriasis. Br J Dermatol 1990; 122 ( Suppl. 26 ): 1 – 3. | en_US |
dc.identifier.citedreference | Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases. N Engl J Med 1992; 326: 1654 – 60. | en_US |
dc.identifier.citedreference | Grossman RM, Chevret S, Abi-Rached J et al. Long-term safety of cyclosporin in the treatment of psoriasis. Arch Dermatol 1996; 132: 623 – 9. | en_US |
dc.identifier.citedreference | Kaoukhov A, Paul C, Lahfa M, Blanchet F, Dubertret L. Renal function during long-term cyclosporin treatment of psoriasis. Ann Dermatol Venereol 2000; 127: 180 – 3. | en_US |
dc.identifier.citedreference | Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366 – 75. | en_US |
dc.identifier.citedreference | Young EW, Ellis CN, Messana JM et al. A prospective study of renal structure and function in patients treated with cyclosporin. Kidney Internat 1994; 46: 1216 – 22. | en_US |
dc.identifier.citedreference | Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis treated with cyclosporine: a 5-yr cohort study. J Invest Dermatol 2003; 120: 211 – 6. | en_US |
dc.identifier.citedreference | Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042 – 5. | en_US |
dc.identifier.citedreference | Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporin A. J Autoimmun 1989; 2: 723 – 31. | en_US |
dc.identifier.citedreference | Jonas S, Rayes N, Neumann U et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporin-based quadruple immunosuppression with an interleukin-2 receptor antibody or anti-thymocyte globulin. Cancer 1997; 80: 1141 – 50. | en_US |
dc.identifier.citedreference | Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999; 140: 237 – 42. | en_US |
dc.identifier.citedreference | Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425 – 9. | en_US |
dc.identifier.citedreference | Margolis D, Biker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778 – 83. | en_US |
dc.identifier.citedreference | Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralens) and UV-A radiation (PUVA); a meta-analysis. Arch Dermatol 1998; 134: 1582 – 5. | en_US |
dc.identifier.citedreference | Kreimer-Erlacher H, Seidl H, Back B, Cerroni L, Kerl H, Wolf P. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients. J Invest Dermatol 2003 April; 120: 676 – 82. | en_US |
dc.identifier.citedreference | Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252 – 8. | en_US |
dc.identifier.citedreference | Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644 – 50. | en_US |
dc.identifier.citedreference | Katz HI. Potential drug interactions with cyclosporine. Int J Dermatol 1997; 36 ( Suppl. 1 ): 18 – 24. | en_US |
dc.identifier.citedreference | 48 Guidelines Subcommittee 1999 World Health Organization-International Society of Hypertension. Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151 – 83. | en_US |
dc.identifier.citedreference | 49 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011 – 53. | en_US |
dc.identifier.citedreference | 50 Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560 – 72. | en_US |
dc.identifier.citedreference | Midtvedt K, Fauchald P, Bergan S et al. C 2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003; 76: 1236 – 8. | en_US |
dc.identifier.citedreference | Cockcroft DW, Goult MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 ( 1 ): 31 – 41. | en_US |
dc.identifier.citedreference | Feutren G, Friend D, Timonen P, Barnes A, Laburte C. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. Br J Dermatol 1990; 122 ( Suppl. 36 ): 85 – 93. | en_US |
dc.identifier.citedreference | Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol 2002; 147: 122 – 9. | en_US |
dc.identifier.citedreference | Clark CM, Kirby B, Morris AD et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279 – 82. | en_US |
dc.identifier.citedreference | Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143 (2): 405 – 7. | en_US |
dc.identifier.citedreference | Ellis CN, Krueger GG for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248 – 55. | en_US |
dc.identifier.citedreference | Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362 – 7. | en_US |
dc.identifier.citedreference | Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol 2002; 27: 591 – 6. | en_US |
dc.identifier.citedreference | Johnston A, Keown PA, Holt DW. Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit 1997; 19: 375 – 81. | en_US |
dc.identifier.citedreference | Johnston A, Holt DW. Bioequivalence criteria for cyclosporine. Transplant Proc 1999; 31: 1649 – 53. | en_US |
dc.identifier.citedreference | Pollard S, Nashan B, Johnston A et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther 2003; 25: 1654 – 69. | en_US |
dc.identifier.citedreference | 63 British National Formulary. Corticosteroids and other immunosuppressants – ciclosporin. September 2003; 46: section 8.2.2 (also available at: http://www.bnf.org ). | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.